Linked Life Data

20975356

Source:http://linkedlifedata.com/resource/pubmed/id/20975356

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11 Suppl 2
pubmed:dateCreated
2010-10-26
pubmed:abstractText
OVO5/EORTC 55855, a study punitively refuting the value of CA-125 in the follow-up of ovarian cancer patients, has many deficiencies, including a heterogeneous ovarian cancer patient population, no control of initial treatment regimens, and no control of subsequent surgery or chemotherapeutic management for recurrence. Recent studies suggest a role for prompt surgery in selected cases of recurrent ovarian cancer with CA-125 elevations, a role for tamoxifen in managing rising CA-125 levels in patients without evidence of disease and the use of platinum doublets for treating recurrent platinum-sensitive disease, none of which were incorporated into OVo5/EORTC 55955.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1525-1438
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S24-6
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Fifth Alon Dembo memorial workshop: case 3.
pubmed:affiliation
Yale University School of Medicine, New Haven, CT 06520, USA. peter.schwartz@yale.edu
pubmed:publicationType
Journal Article, Review